scholarly journals CpG increases vaccine antigen-specific cell-mediated immunity when administered with hepatitis B vaccine in HIV infection

2008 ◽  
Vol 6 (1) ◽  
pp. 4 ◽  
Author(s):  
Jonathan B Angel ◽  
Curtis L Cooper ◽  
Jennifer Clinch ◽  
Charlene D Young ◽  
Andreane Chenier ◽  
...  
2011 ◽  
Vol 54 ◽  
pp. S150
Author(s):  
J. Rybczynska ◽  
U. Sharapov ◽  
E. Bancroft ◽  
K. Tran ◽  
J. Drobeniuc ◽  
...  

2014 ◽  
Vol 10 (4) ◽  
pp. 1013-1023 ◽  
Author(s):  
Yibin Zhu ◽  
Tianying Zhang ◽  
Jinghua Zhao ◽  
Zusen Weng ◽  
Quan Yuan ◽  
...  

1987 ◽  
Vol 3 (3) ◽  
pp. 323-324
Author(s):  
P. Amoroso ◽  
C. Izzo ◽  
R. Smeraglia ◽  
G. Lettieri ◽  
G. Maio ◽  
...  

2016 ◽  
Vol 62 (3) ◽  
pp. 40-48
Author(s):  
Amit Gupta ◽  
Sushama R. Chaphalkar

Summary Introduction: Numerous metabolites present in the aqueous extract from plants are responsible for inducing adjuvant activity against rubella and hepatitis B vaccine antigen (HBsAg). One of the medicinal plants, Adhatoda vasica has been pointed out with great potential of vaccine adjuvant property. Objective: The objective of our study is to evaluate the adjuvant potential of aqueous leaves extract of Adhatoda vasica against rubella and hepatitis B vaccine antigen (HBsAg). Methods: For these studies, our group evaluated the antibody (IgG) titre of HBsAg and rubella vaccine antigen using variable doses (0.625–5 mg) of aqueous leaves extract of Adhatoda vasica and also determined the lymphocyte (splenocyte) proliferation assay (0.625–5 mg; 50 μl) in mice model studies ex vivo (i.e. immunized with HBsAg subcutaneously). Results: The results showed that aqueous leaves extract showed anti-HBsAg and anti-rubella titre and also enhanced the lymphocyte proliferation assay at higher doses (5 mg) as compared to control. Conclusion: Aqueous leaves extract of Adhatoda vasica showed adjuvant activity against HBsAg and rubella vaccine antigen.


2017 ◽  
Vol 2 (1) ◽  
pp. 66 ◽  
Author(s):  
Robert M. Paris ◽  
Lucimar G. Milagres ◽  
Eirini Moysi ◽  
Jason F. Okulicz ◽  
Brian K. Agan ◽  
...  

Background: Why HIV-infected individuals have poor responses to standard dose and schedule hepatitis B virus immunization is not well understood.Methods: We compared the serologic and cellular immune profiles of treated HIV-infected individuals with similar durations of infection and preserved CD4 counts (>350 cells/microliter) by hepatitis B vaccine (HBV) response before and after vaccination.Results: Similar levels of immune activation and plasma cytokine profile were found between non-responders and responders. The baseline plasma levels of CXCL-13, a surrogate of germinal center reactivity, were significantly lower in HBV responders compared to HBV non-responders and were a predictor of both vaccine response and titer. Furthermore, response to HBV vaccination was associated with a significantly higher frequency of circulating IgGhigh memory B cells post vaccination and preserved Th1 antigen-specific T-cell responses.Conclusions: Taken together, our data suggest that preserved Th1 responses are associated with hepatitis B vaccine response in treated HIV infection.


1990 ◽  
Vol 104 (1) ◽  
pp. 143-149 ◽  
Author(s):  
E. Dahl-Hansen ◽  
J. Chr. Siebke ◽  
S. S. Frøland ◽  
M. Degré

SUMMARYThe immunogenicity and reactogenicity of two preparations of yeast-derived hepatitis B vaccinces were compared in healthy adult populations. The two groups were vaccinated in parallel, but they were not matched for age and sex. All subjects seroconverted, and 9 months after the first vaccine dose, all had anti HBs titres of at least 10 IU/1. The anti-HBs titres were higher in the group of subjects given 20μg vaccine antigen made by Smith Kline & RIT (GMT 2943 at 9 months) compared to those who received 10μg of vaccine made by Merck, S harp & Dohme (GMT 729 at 9 months). Adverse effects were recorded in 32·0 and 44·7% of the participants, but these were limited to minor local and general reactions. In the present study both preparations were safe and efficient.


Vaccine ◽  
2008 ◽  
Vol 26 (8) ◽  
pp. 1032-1037 ◽  
Author(s):  
Sérgio Júlio Fernandes ◽  
Natasha Slhessarenko ◽  
Francisco José Dutra Souto

2007 ◽  
Vol 41 (9) ◽  
pp. 14
Author(s):  
MIRIAM E. TUCKER

2012 ◽  
Vol 46 (2) ◽  
pp. 10
Author(s):  
CHRISTOPHER J. HARRISON

Sign in / Sign up

Export Citation Format

Share Document